Biodesix Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Broomfield CO United States (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2012
NCT01652469
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Biodesix, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

docetaxel (taxotere) (1 trial)

erlotinib (tarceva) (2 trials)

Drugs in Phase 2 Trials (2)

cytarabine (cytosar-u) (1 trial)

ficlatuzumab (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4